FGFR a promising druggable target in cancer: Molecular biology and new drugs - PubMed (original) (raw)
Review
doi: 10.1016/j.critrevonc.2017.02.018. Epub 2017 Mar 23.
Roberto Borea 2, Andreia Coelho 2, Shahanavaj Khan 3, António Araújo 4, Pablo Reclusa 2, Tindara Franchina 5, Nele Van Der Steen 6, Peter Van Dam 2, Jose Ferri 2, Rafael Sirera 2, Aung Naing 7, David Hong 7, Christian Rolfo 8
Affiliations
- PMID: 28427515
- DOI: 10.1016/j.critrevonc.2017.02.018
Review
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta et al. Crit Rev Oncol Hematol. 2017 May.
Abstract
Introduction: The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently, alterations of FGFR have been reported to be important for progression and development of several cancers. In this setting, different studies are trying to evaluate the efficacy of different therapies targeting FGFR.
Areas covered: This review summarizes the current status of treatments targeting FGFR, focusing on the trials that are evaluating the FGFR profile as inclusion criteria: Multi-Target, Pan-FGFR Inhibitors and anti-FGF (Fibroblast Growth Factor)/FGFR Monoclonal Antibodies.
Expert opinion: Most of the TKR share intracellular signaling pathways; therefore, cancer cells tend to overcome the inhibition of one tyrosine kinase receptor by activating another. The future of TKI (Tyrosine Kinase Inhibitor) therapy will potentially come from multi-targeted TKIs that target different TKR simultaneously. It is crucial to understand the interaction of the FGF-FGFR axis with other known driver TKRs. Based on this, it is possible to develop therapeutic strategies targeting multiple connected TKRs at once. One correct step in this direction is the reassessment of multi target inhibitors considering the FGFR status of the tumor. Another opportunity arises from assessing the use of FGFR TKI on patients harboring FGFR alterations.
Keywords: Cancer; FGF; FGFR; FGFR inhibitors.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
- Future applications of FGF/FGFR inhibitors in cancer.
Ghedini GC, Ronca R, Presta M, Giacomini A. Ghedini GC, et al. Expert Rev Anticancer Ther. 2018 Sep;18(9):861-872. doi: 10.1080/14737140.2018.1491795. Epub 2018 Jul 2. Expert Rev Anticancer Ther. 2018. PMID: 29936878 Review. - Targeting the fibroblast growth factor receptor family in cancer.
Hallinan N, Finn S, Cuffe S, Rafee S, O'Byrne K, Gately K. Hallinan N, et al. Cancer Treat Rev. 2016 May;46:51-62. doi: 10.1016/j.ctrv.2016.03.015. Epub 2016 Apr 12. Cancer Treat Rev. 2016. PMID: 27109926 Review. - Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G. Repetto M, et al. Expert Rev Clin Pharmacol. 2021 Oct;14(10):1233-1252. doi: 10.1080/17512433.2021.1947246. Expert Rev Clin Pharmacol. 2021. PMID: 34591728 Review. - FGFR-TKI resistance in cancer: current status and perspectives.
Yue S, Li Y, Chen X, Wang J, Li M, Chen Y, Wu D. Yue S, et al. J Hematol Oncol. 2021 Feb 10;14(1):23. doi: 10.1186/s13045-021-01040-2. J Hematol Oncol. 2021. PMID: 33568192 Free PMC article. Review. - Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
Agrawal S, Maity S, AlRaawi Z, Al-Ameer M, Kumar TKS. Agrawal S, et al. Curr Drug Targets. 2021;22(2):214-240. doi: 10.2174/1389450121999201012201926. Curr Drug Targets. 2021. PMID: 33045958 Review.
Cited by
- Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Tian Z, Niu X, Yao W. Tian Z, et al. Front Oncol. 2020 Aug 28;10:1642. doi: 10.3389/fonc.2020.01642. eCollection 2020. Front Oncol. 2020. PMID: 32984034 Free PMC article. Review. - Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer.
Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D. Sobhani N, et al. Cells. 2018 Jul 15;7(7):76. doi: 10.3390/cells7070076. Cells. 2018. PMID: 30011957 Free PMC article. Review. - Escalated Oxycodone Self-Administration Causes Differential Striatal mRNA Expression of FGFs and IEGs Following Abstinence-Associated Incubation of Oxycodone Craving.
Blackwood CA, Leary M, Salisbury A, McCoy MT, Cadet JL. Blackwood CA, et al. Neuroscience. 2019 Sep 1;415:173-183. doi: 10.1016/j.neuroscience.2019.07.030. Epub 2019 Jul 24. Neuroscience. 2019. PMID: 31351142 Free PMC article. - Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
Lang L, Teng Y. Lang L, et al. Cells. 2019 Jan 9;8(1):31. doi: 10.3390/cells8010031. Cells. 2019. PMID: 30634399 Free PMC article. Review. - Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas.
Darvishi E, Slemmons K, Wan Z, Mitra S, Hou X, Parmentier JH, Eddie Loh YH, Helman LJ. Darvishi E, et al. Neoplasia. 2020 Jul;22(7):274-282. doi: 10.1016/j.neo.2020.05.001. Epub 2020 May 25. Neoplasia. 2020. PMID: 32464274 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources